The role of targeted agents in adjuvant therapy for non-small cell lung cancer.

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

The recent survival benefit of adjuvant chemotherapy in early stage non-small cell lung cancer provides optimism for the future success of targeted therapy in this setting. It is important that we begin to explore molecularly targeted agents in the adjuvant arena, but how best to accomplish this in the face of these new findings presents a challenge. Criteria for selecting promising targeted therapies and optimal trial designs to evaluate them expeditiously in the adjuvant setting are clearly needed.

Original languageEnglish (US)
JournalClinical cancer research : an official journal of the American Association for Cancer Research
Volume11
Issue number13 Pt 2
StatePublished - Jul 1 2005
Externally publishedYes

Fingerprint

Non-Small Cell Lung Carcinoma
Adjuvant Chemotherapy
Therapeutics
Optimism

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

@article{1ebf291f1e8a400dab7d304cefb45947,
title = "The role of targeted agents in adjuvant therapy for non-small cell lung cancer.",
abstract = "The recent survival benefit of adjuvant chemotherapy in early stage non-small cell lung cancer provides optimism for the future success of targeted therapy in this setting. It is important that we begin to explore molecularly targeted agents in the adjuvant arena, but how best to accomplish this in the face of these new findings presents a challenge. Criteria for selecting promising targeted therapies and optimal trial designs to evaluate them expeditiously in the adjuvant setting are clearly needed.",
author = "Karen Kelly",
year = "2005",
month = "7",
day = "1",
language = "English (US)",
volume = "11",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "13 Pt 2",

}

TY - JOUR

T1 - The role of targeted agents in adjuvant therapy for non-small cell lung cancer.

AU - Kelly, Karen

PY - 2005/7/1

Y1 - 2005/7/1

N2 - The recent survival benefit of adjuvant chemotherapy in early stage non-small cell lung cancer provides optimism for the future success of targeted therapy in this setting. It is important that we begin to explore molecularly targeted agents in the adjuvant arena, but how best to accomplish this in the face of these new findings presents a challenge. Criteria for selecting promising targeted therapies and optimal trial designs to evaluate them expeditiously in the adjuvant setting are clearly needed.

AB - The recent survival benefit of adjuvant chemotherapy in early stage non-small cell lung cancer provides optimism for the future success of targeted therapy in this setting. It is important that we begin to explore molecularly targeted agents in the adjuvant arena, but how best to accomplish this in the face of these new findings presents a challenge. Criteria for selecting promising targeted therapies and optimal trial designs to evaluate them expeditiously in the adjuvant setting are clearly needed.

UR - http://www.scopus.com/inward/record.url?scp=24944465616&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=24944465616&partnerID=8YFLogxK

M3 - Article

C2 - 16000608

AN - SCOPUS:24944465616

VL - 11

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 13 Pt 2

ER -